CHMP recommends Merck's Prevymis for CMV

EMA's CHMP recommended approval of oral and IV formulations of Prevymis letermovir (MK-8228; AIC246) from Merck & Co. Inc. (NYSE:MRK) to prevent cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation (HSCT).

FDA approved Prevymis on Nov. 9 (see BioCentury, Nov. 9)...